Skip to content
Search

May 2023 / VIDEO

Medical Technology Industry Well-Positioned Post-Covid

Key Insights

  • Many businesses in the health care sector can consistently grow revenue and earnings, even in challenging macroeconomic environments.
  • The medical technology, or medtech, industry is one area of health care that we believe is particularly well positioned for the near term.
  • We prefer health care firms with high recurring revenues from consumables and services as opposed to those that are reliant on sales of capital equipment.

A variety of unique subsectors make up the health care sector, with business models ranging from pharmaceuticals, where companies are developing cutting-edge medicines to treat cancer, inflammatory diseases, and other conditions, to the consumer-facing hospitals and providers that are delivering clinical care to patients.

The common thread across the health care sector is that many of these businesses can consistently grow revenue and earnings, even in challenging macroeconomic environments. With the potential for a recession looming, this characteristic may prove valuable.

There are two primary reasons for this resilience. First, demand for health care is noncyclical—it is one of the last areas where consumers cut spending when times get tough.

Second, secular demographic trends support health care demand. Since 2010, the percentage of Americans 65 and older has grown rapidly, driven by the aging of the baby boomer generation; rising life expectancy should support the continuation of this trend. According to projections as of February 2020 from the U.S. Census Bureau, by 2060 nearly one in four Americans will be 65 or older, up from 13% in 2010 and 17% in 2020.

Of course, utilization of the health care system increases with age, with people age 65 and over spending much more per capita on health care than younger cohorts. A 2021 study by the Kaiser Family Foundation found that people 65 and over accounted for 35% of health care spending despite making up just 17% of the U.S. population. The secular growth of this demographic should drive increased demand for prescription drugs, medical devices, and health care services for years to come.

The medical technology, or medtech, industry is one area of health care that we believe is particularly well positioned for the near term. The last few years have been unusually challenging ones for medtech, where these businesses lagged their earnings potential due to a combination of factors largely outside of their control.

Medtech companies saw a sharp decline in revenue and earnings early in the pandemic as health care systems around the world deferred all but the most urgent medical procedures in order to preserve capacity and resources for COVID patients. For their part, patients, wary of COVID, avoided interactions with the health care system.

Even as patients slowly returned to the system, procedure volumes remained stubbornly below pre-COVID levels through 2021 and most of 2022 due, in part, to staffing shortages that prevented health care providers from catching up on all of the deferred procedures. At the same time, supply chain headwinds and input cost inflation put downward pressure on medtech companies’ profitability.

However, we believe the medtech industry is now well positioned to rebound from these difficulties. Procedure volumes are normalizing as hospital staffing shortages have started to ease, which should support healthy organic revenue growth.

Easing cost pressures for raw materials and freight alongside operating leverage should drive margin expansion starting in the second half of 2023.

It is important to note that not all medtech companies are created equal. In weaker economic environments, hospitals tend to reduce capital spending on large-ticket items. This phenomenon drives our cautious view on companies that are overly reliant on sales of capital equipment and our preference for those with a high mix of recurring revenues from consumables and services.

IMPORTANT INFORMATION

This material is being furnished for general informational purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, and prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.

The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.

Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources' accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date noted on the material and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.

The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request.  

It is not intended for distribution to retail investors in any jurisdiction.

Canada—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.’s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.

© 2023 T. Rowe Price. All rights reserved. T. ROWE PRICE, INVEST WITH CONFIDENCE, and the bighorn sheep design are, collectively and/or apart, trademarks or registered trademarks of T. Rowe Price Group, Inc.

Previous Article

May 2023 / VIDEO

US Equities: Outlook amidst the volatility
Next Article

May 2023 / GLOBAL EQUITIES

Meet Dominic Rizzo
202304-2833306